Male study dosing
2 mg once dailyOriginal formulation in clinical trials
TESAROSSA · TESAMORELINMGMT RESEARCH
GROWTH HORMONE RESEARCH
TESAROSSA 10 mg
Tesamorelin · GHRH analogue
A 10 mg lyophilized research compound for investigating GHRH receptor signaling, endogenous growth hormone release, and the GH / IGF-1 axis.
$120.00 CADPer vial · 10 mg option
01 / SOURCINGCanadian supplier partner
02 / QUALITYCOA pending
03 / FULFILLMENTToronto dispatch
04 / FORMATLyophilized powder
COA pending. Independent testing will be performed by SideChain Analytics in Mississauga, Ontario.
BAC Water offer +
Buy 2–5 eligible compound vials: receive one free 3 mL BAC Water. Buy 6 or more: receive one free BAC Water per eligible compound vial. Mix available compounds. AFTERBURN and RETROD Duo are excluded.
View BAC WaterTax-inclusive CAD pricing. E-transfer accepted · Credit cards coming soon.
Mix Easy · Open the calculator ↗Female study dosing
2 mg once dailyOriginal formulation in clinical trials
Frequency in trials
Once dailyPublished clinical study schedule
Route in trials
SubcutaneousClinical study administration
Reported half-life
Formulation-dependent8 minutes reported for EGRIFTA SV
Post-cycle PCT
Not establishedNo validated PCT protocol
The original Tesamorelin trials used 2 mg once daily in adults with HIV-associated abdominal fat accumulation, without separate male/female regimens. These are study details, not directions for TESAROSSA vials. Published study ↗ · Formulation-specific pharmacokinetics ↗
DESCRIPTION
What is TESAROSSA 10 mg?
TESAROSSA is our name for Tesamorelin, a synthetic growth hormone–releasing hormone (GHRH) analogue. It acts through the GHRH receptor to stimulate endogenous growth hormone release and downstream IGF-1 signaling.
Your selected vial contains 10 mg of labeled lyophilized compound. This is the total vial amount, not a dose or a solution concentration. TESAROSSA is sourced through a Canadian supplier partner and is not filled in-house by MGMT Research.
COA results are pending. Independent testing will be performed by SideChain Analytics in Mississauga, Ontario; verified purity and net-content figures will be published when available.
BENEFITS / RESEARCH INTERESTThe GHRH pathway.
The GHRH pathway.
A focused research profile.
Tesamorelin research explores growth hormone signaling and body composition, including visceral adipose tissue in HIV-associated lipodystrophy. Findings concern studied pharmaceutical formulations, not promised outcomes from TESAROSSA.
- Visceral adipose tissue: abdominal fat endpoints in controlled studies.
- GH / IGF-1 signaling: endocrine responses to GHRH receptor activation.
- Metabolic markers: lipid and glucose measures assessed in clinical research.
Product specifications & handling +
- Product
- TESAROSSA · Tesamorelin
- Selected quantity
- 10 mg
- Form
- Lyophilized powder
- Receptors
- GHRH receptor / GH–IGF-1 axis
- Testing
- COA pending · SideChain Analytics
- Origin / dispatch
- Canadian supplier partner / Toronto
Follow batch-specific supplier instructions and your laboratory’s validated storage and reconstitution procedures. A prepared solution’s shelf life has not been established for this product.
Orders received before 12 PM EST ship the same business day.
COA pending. Purity and net-content results will be published when the batch-specific report is available.
MIX EASYYour mixture.
Your mixture.
Made clear.
Select your compound, vial amount, diluent volume, and sample amount. Our calculator converts your inputs into a concentration, volume, and U-100 syringe marking.
01
Set your mixture
mg
mL
Enter an example amount to calculate its volume.
02
Your measurement
TESAROSSA
20units
0.2 mL of solution per sample
U-100 scale1 mL = 100 units
Concentration10 mg/mL
Full samples per vial5
THE CALCULATION
2 mg ÷ 10 mg/mL = 0.2 mL
How to read this calculator +
Concentration = vial amount ÷ solution volume. Sample volume = sample amount ÷ concentration. U-100 scale units = volume in mL × 100; these are volume markings, not units of compound potency.
This example assumes the final solution volume equals the diluent volume entered, and that the compound dissolves completely. It does not establish solubility, compatibility, stability, or an administration dose.
Decimal measurements are mathematical results and may fall between markings. Full samples are rounded down; they do not account for handling losses.
The calculator checks concentration mathematics. It does not select a treatment dose or establish compatibility, sterility, or stability. SEMARO is temporarily unavailable and is omitted from this selector. BAC Water is the diluent, not a peptide.
SIDE EFFECTS & CONSIDERATIONS
What the research reports.
Reported adverse reactions to pharmaceutical Tesamorelin include joint and muscle pain, injection-site reactions, and fluid retention. Important considerations include elevated IGF-1, glucose intolerance, and hypersensitivity.
Pharmaceutical formulations have specific contraindications, including active malignancy, pregnancy, and disruption of the hypothalamic–pituitary axis. TESAROSSA research vials are not interchangeable with approved EGRIFTA formulations.
Product-specific considerations
- Independent identity, purity, and content results are pending for TESAROSSA.
- A labeled 10 mg quantity does not establish a therapeutic dose.
- Mixing calculations cannot establish sterility, stability, or suitability for administration.
DOSAGE GUIDELINES / STUDY CONTEXT
Vial amount is not a dose.
Your selected TESAROSSA vial is labeled 10 mg. The clinical information below does not establish a dosing regimen for this research product.
Published Tesamorelin study
The 2007 trial studied 2 mg once daily for 26 weeks in adults with HIV-associated abdominal fat accumulation. It used a specific clinical formulation under a controlled protocol.
Approved EGRIFTA formulations have different doses and preparation requirements. Their instructions do not transfer to TESAROSSA vials. Laboratory sample amounts and preparation procedures should come from your validated protocol.
Open Mix Easy ↗Read the original trial ↗